

Chapter 5: Influenza

Lynnette Brammer, MPH; Keiji Fukuda, MD; Alexander Klimov, PhD; Nancy Cox, PhD

I. Disease description

Aspirin and other salicylate-containing medications are contraindicated for children and adolescents with influenza-like illness, as their use during influenza infection constitutes a major risk for Reye syndrome.

Influenza is an acute respiratory disease caused by influenza type A or B viruses. The incubation period ranges from 1–4 days. Peak virus shedding usually occurs from 1 day before onset of symptoms to 3 days after. Typical features of influenza include abrupt onset of fever and respiratory symptoms such as cough (usually nonproductive), sore throat, and coryza, as well as systemic symptoms such as headache, muscle aches, and fatigue. The clinical severity of infection can range from asymptomatic illness to primary viral pneumonia and death. Acute symptoms generally last 2–4 days although malaise and cough may continue for 2 weeks or longer. Complications of influenza infection include secondary bacterial pneumonia and exacerbation of underlying chronic health conditions. Complications occurring in children can include otitis media, myositis, myocarditis, toxic-shock syndrome, and Reye syndrome. Aspirin and other salicylate-containing medications are contraindicated for children and adolescents with influenza-like illness, as their use during influenza infection constitutes a major risk factor for Reye syndrome.

The sharp rise in acute respiratory illnesses that occurs during influenza epidemics results in increased numbers of visits to physicians' offices, walk-in clinics, and emergency rooms. Hospitalizations for pneumonia and other complications also increase. The elderly and persons with certain underlying health problems are at increased risk for complications of influenza and hospitalization. Influenza epidemics, particularly epidemics caused by influenza A (H3N2) viruses, are associated with increased mortality. During each of 11 of 23 influenza seasons from the 1972–73 season through the 1994–95 season, more than 20,000 influenza-associated deaths occurred, and more than 40,000 deaths occurred during each of six of these seasons.^{1,2} More than 90% of influenza-associated deaths now occur among persons age 65 years and older.³

II. Background

Influenza type A and type B viruses can cause epidemics of illness in people.⁴ Influenza type A viruses are divided into subtypes based on surface proteins called hemagglutinin (HA) and neuraminidase (NA). The two influenza A subtypes that have co-circulated in human populations since 1977 are influenza A (H1N1) and A (H3N2). Influenza A and B viruses both undergo gradual, continuous change in the HA and NA proteins, known as *antigenic drift*. As a result of these antigenic changes, antibodies produced to influenza from infection or vaccination with earlier strains may not be protective against viruses circulating in later years. Consequently, yearly epidemics usually occur in populations and multiple infections can occur over a person's lifetime. Antigenic changes also necessitate frequent updating of influenza vaccine components to

ensure that the vaccine is matched to circulating viruses. In addition to antigenic drift, influenza type A viruses can undergo a more dramatic and abrupt type of antigenic change called an *antigenic shift*, which occurs when viruses belonging to a new influenza A subtype bearing either a novel HA protein or novel HA and NA proteins begin circulating among people. While antigenic drift occurs continuously, antigenic shift occurs infrequently. When antigenic shift does occur, a large proportion, or even all, of the world's population has no antibody against the new virus. This can result in a worldwide epidemic called a *pandemic*. During the 20th century, pandemics occurred in 1918 (type A [H1N1]), 1957 (A [H2N2]), and 1968 (A [H3N2]).

III. Vaccination

Annual influenza vaccination is recommended for persons at high risk for influenza-associated complications, persons 50–64 years of age, and persons such as health-care providers and household contacts who have close contact with high-risk persons.² Persons at increased risk for influenza-related complications include:

- Persons \geq 65 years of age
- Residents of nursing homes and other chronic-care facilities that house persons of any age with chronic medical conditions
- Adults and children with chronic pulmonary or cardiovascular disorders, including children with asthma
- Adults and children who required regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications)
- Children and adolescents (6 months–18 years of age) who are receiving long-term aspirin therapy and, therefore, might be at risk for developing Reye syndrome after influenza
- Women who will be in the second or third trimester of pregnancy during the influenza season

Annual vaccination also is recommended for persons aged 50–64 years because a large proportion of persons in this age group have at least one chronic medical problem that puts them at high risk for complications from influenza. Age-based strategies have been more successful in increasing vaccine coverage than patient-selection strategies based on medical conditions.

Studies indicate that children $<$ 2 years of age are also at increased risk for influenza-related hospitalization.⁵⁻⁷ Because of this increased risk, influenza vaccination is encouraged for all children aged 6–23 months when feasible. Also, vaccination is encouraged for household contacts and out-of-home caretakers of children $<$ 2 years old, particularly for contacts of infants up to 5 months old, because children in this age group are at the greatest risk of influenza-related complications, and influenza vaccines are not approved by the U.S. Food and Drug Administration (FDA) for use among children aged $<$ 6 months.²

Influenza vaccine is a trivalent vaccine containing inactivated influenza A (H3N2), influenza A (H1N1), and influenza B strains selected to represent the strains judged most likely to circulate during the influenza season in the United States. Typically one or two of the three vaccine components are updated each year to provide a better antigenic match with circulating viruses. The efficacy of the vaccine depends on the match between the vaccine strains and the circulating strains as well as the recipient's age, immunocompetence, and previous exposure to influenza. In healthy persons < 65 years of age, influenza vaccine is approximately 70%–90% effective in preventing illness when the match between the vaccine strains and circulating viruses is good.⁸ The effectiveness of influenza vaccine in preventing hospitalization for pneumonia and influenza among elderly persons (≥ 65 years) living in settings other than nursing homes or similar chronic-care facilities ranges from 30%–70%.^{9,10} Among elderly persons residing in nursing homes, influenza vaccine is most effective in preventing severe illness, secondary complications, and death. Studies among this population have indicated that the vaccine can be 50%–60% effective in preventing hospitalization and pneumonia and 80% effective in preventing death, even though efficacy in preventing influenza illness may often be in the range of 30%–40%.^{11,12} Achieving a high rate of vaccination among nursing home residents can reduce the spread of infection in a facility through herd immunity, thus preventing disease.¹³ Further, vaccination of nursing home staff has been associated with decreased mortality among residents, presumably by further lessening transmission from health-care workers to patients.¹⁴

IV. Antiviral drugs

Four currently approved antiviral medications are available in the United States: amantadine, rimantadine, zanamivir, and oseltamivir. Amantadine and rimantadine interfere with the replication cycle of influenza A viruses and can be used for prophylaxis or treatment during an epidemic. Both amantadine and rimantadine can prevent influenza A infection if given before exposure and can reduce the severity and duration of the symptoms of an influenza A illness if given within 48 hours of the onset of illness. Neither drug is effective against influenza B viruses.² Zanamivir and oseltamivir are neuraminidase inhibitors with activity against both influenza A and B viruses. Zanamivir and oseltamivir are approved for treatment of uncomplicated influenza. Oseltamivir is also approved for chemoprophylaxis of influenza in persons ≥ 13 years of age. When administered prophylactically to healthy adults or children, amantadine and rimantadine are approximately 70%–90% effective in preventing illness from influenza A infection;¹⁵⁻¹⁷ oseltamivir is approximately 70%–90% effective in preventing illness from influenza A or B infection.¹⁸⁻²⁰

V. Importance of rapid case identification

Rapid identification of influenza virus infection can assist health-care providers in determining optimal strategies for preventing or treating influenza. In an institutional setting this may include the administration of antiviral drugs to reduce the spread of influenza. Rapid diagnosis of influenza illness occurring early in

the season can be used to prompt members of target groups to receive vaccine before illness becomes widespread in the community.

VI. Importance of surveillance

Because influenza viruses undergo constant antigenic change, both virologic surveillance (in which influenza viruses are isolated for antigenic analysis) and disease surveillance are necessary to identify influenza virus variants and to monitor their health impact in populations. This information is vital for selecting the optimal influenza vaccine components each year. Knowledge of the prevalent circulating virus type can also assist health-care providers in making treatment decisions. For example, if influenza activity has been confirmed in a community, antiviral drugs may be used to treat patients with influenza-like illness within 48 hours of onset of symptoms to reduce the length and severity of illness. With the increased use of antiviral drugs, virologic surveillance also is important for the identification of drug-resistant strains of influenza viruses.

VII. Importance of vaccination

Annual vaccination against influenza is recommended for persons at high risk for influenza-associated complications, their close contacts, and person 50–64 years of age. Previous vaccination may offer little or no protection against strains that have undergone substantial antigenic drift. Even when a vaccine component remains the same, immunity induced by the vaccine declines over time and may not be protective during the next season. Finally, while antiviral agents can be a useful adjunct to vaccination, chemoprophylaxis is not a substitute for vaccination. Annual vaccination of persons at high risk for influenza-associated complications is the most effective means of reducing the impact of influenza.

Annual vaccination of persons at high risk of influenza-associated complications is the most effective means of reducing the impact of influenza.

VIII. Disease reduction goals

The U.S. Department of Health and Human Services has established a Healthy People 2010 goal of increasing rates of pneumococcal and influenza vaccination among institutionalized adults and all persons age 65 and older to at least 90%, and to at least 60% among noninstitutionalized, high-risk persons age 18–64 years.²¹

IX. Case definitions

Definitive diagnosis of influenza requires laboratory confirmation in addition to signs and symptoms. Case definitions for influenza-like illness vary depending on the purpose for which they are used. A case definition of fever $\geq 100^{\circ}\text{F}$ and cough or sore throat is used by CDC in its sentinel physician surveillance system, in which health-care providers report the total number of patient visits and the number of patients seen for influenza-like illness each week.

X. Laboratory testing

Influenza infection cannot be diagnosed based on signs and symptoms. Laboratory testing is necessary to confirm the diagnosis.

Although influenza infection generally leads to more severe illness among adults than other respiratory viruses, individual cases of influenza infection cannot be distinguished from other respiratory virus infections based on clinical information alone. Laboratory testing is necessary to confirm the diagnosis. Methods available for the diagnosis of influenza include virus isolation (standard methods and rapid culture assays), detection of viral antigens (enzyme immunoassays [EIA], immunofluorescent antibody [IFA] testing), commercially available rapid diagnostic kits, and less frequently, electron microscopy, molecular detection (polymerase chain reaction [PCR]), and serologic testing.^{22,23} Contact your state health department for information regarding the availability of testing and the methods used.

For additional information on laboratory support for surveillance of vaccine-preventable diseases, see Chapter 19, "Laboratory Support for Surveillance of Vaccine-Preventable Diseases."

Virus isolation and rapid culture assays

Virus isolation is the gold standard for influenza diagnosis. Appropriate clinical specimens include nasal washes, nasopharyngeal aspirates, nasal and throat swabs, transtracheal aspirates, and bronchoalveolar lavage. Specimens should be taken within 72 hours of onset of illness. Influenza viruses can be isolated in fertilized chicken eggs or in tissue culture. The Madin-Darby canine kidney cell line and primary rhesus or cynomolgus monkey kidney cells support the growth of influenza viruses. Virus isolation has the advantage of producing quantities of virus sufficient for full antigenic characterization, which is required for determining vaccine match. Standard isolation procedures have the disadvantage of requiring several days to obtain results, thereby making them less useful to the clinician.

Rapid culture assays that use immunologic methods to detect viral antigens in cell culture are available. The results of these assays can be obtained in 18–40 hours as compared with an average of 4.5 days to obtain positive results from standard culture.²³

Antigen detection and molecular detection assays

Several methods exist for the diagnosis of influenza infection directly from clinical material. Cells from the clinical specimen can be stained using an immunofluorescent antibody that reveals the presence of viral antigen. Nasal washes, nasopharyngeal aspirates, nasal and throat swabs, gargling fluid, transtracheal aspirates, and bronchoalveolar lavage are suitable clinical specimens. Commercially available kits test for the presence of viral antigens. Currently available test kits fall into three groups; the first detects only influenza type A viruses, while the second detects both influenza type A and B viruses but

does not differentiate between virus types, and the third detects both influenza type A and B viruses and distinguishes between the two. Results of these rapid antigen detection tests can be available in less than 1 hour. Another less frequently used antigen detection method is immunostaining and visualization of viral antigens by electron microscopy.

Molecular detection methods include detection of viral RNA by molecular hybridization and reverse transcription PCR. When direct antigen detection or molecular detection methods are used for the diagnosis of influenza, it is important to collect and save an aliquot of the clinical sample for possible further testing. These samples may be used for culture confirmation of direct test results and isolation for subtyping influenza A isolates by the state public health laboratory. For some rapid testing methods the media used to store the specimen is inappropriate for viral culture; in this case, it is necessary to collect two separate specimens.

Full antigenic characterization of the virus may be performed by the U.S. World Health Organization (WHO) Collaborating Center for Surveillance, Epidemiology, and Control of Influenza, Influenza Branch, CDC. Characterization of isolates is necessary for the detection and tracking of antigenic variants, an essential part of the selection of optimal influenza vaccine components.

Serologic testing

Paired serum specimens are required for serologic diagnosis of influenza infection. The acute specimen should be collected within 1 week of the onset of illness and preferably within 2–3 days. The convalescent sample should be collected approximately 2–3 weeks later. Hemagglutination inhibition tests are the preferred method of serodiagnosis. A positive result is a four-fold or greater rise in titer between the acute and convalescent samples to one type or subtype of virus. For example, if the initial serum dilution is 1:10, two-fold serial dilutions would result in serum concentrations of 1:10, 1:20, 1:40, 1:80, etc. A four-fold or higher increase in titer between the acute and convalescent phase sera (e.g., from 1:20 to 1:80 or higher) is considered positive. A two-fold increase between the two sera (e.g., from 1:20 to 1:40) is within the variability of the test and is not considered a positive finding. Vaccination history of the patient must also be taken into account to assure that a rise in titer reflects infection rather than a recent influenza vaccination. Because most human sera contain antibodies to influenza, diagnosis of influenza cannot be made from a single serum sample. While serologic testing can be useful in certain situations where viral culture is not possible or in special studies, serologic diagnosis of influenza is not accepted for the purposes of national surveillance due to a lack of standardized testing methods and interpretation.

XI. Reporting

Influenza infection is not reported through the National Notifiable Diseases Surveillance System (NNDSS). Local health departments should contact the state health department for guidelines on reporting individual cases or outbreaks of influenza.

Influenza surveillance in the United States consists of four surveillance systems:

- Network of U.S. WHO and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories
- Sentinel Physician Surveillance System
- 122 Cities Mortality Reporting System
- State and Territorial Epidemiologists reports of influenza activity level

In addition, outbreaks of influenza or influenza-like illness may be reported to CDC from other sources such as a state health department, a collaborating hospital or university laboratory, or an institution experiencing an outbreak.

WHO and NREVSS collaborating laboratories

Each week from October through May, approximately 120 WHO and NREVSS collaborating laboratories report the total number of specimens received for respiratory virus testing and the number of positive isolations of influenza A (H1N1), A (H3N2), A (not subtyped), or B. WHO collaborating laboratories report these data by age group (in years, < 1, 1-4, 5-24, 25-44, 45-64, ≥ 65, or unknown). The laboratories participating are in state or local health departments, universities, and hospitals. The information gathered through this system is either recorded on facsimile forms (CDC form CDC 55.31) and faxed to CDC, or transmitted to CDC via the Public Health Laboratory Information System (PHLIS) or by touch-tone telephone. A subset of the isolates obtained in these laboratories is submitted to the WHO Collaborating Center for Surveillance, Epidemiology, and Control of Influenza at CDC for complete antigenic characterization and antiviral resistance testing.

Sentinel Physician Surveillance Network

Each week from October through May, approximately 700 physicians report the number of patient visits for the week and the number of those patients examined for influenza-like illness by age group in years (0-4, 5-24, 25-64, ≥ 65). The physicians may collect nasal and throat swabs for virus isolation. Data are reported electronically to CDC either by touch-tone telephone, through the Internet, or by fax (CDC form CDC 55.20) each week.

122 Cities Mortality Reporting System

Each week throughout the year the vital statistics offices of 122 cities report the total number of death certificates filed due to all causes for that week and the number of deaths for which pneumonia or influenza was mentioned in any position on the certificate. This information is reported to the Epidemiology Program Office (EPO), CDC each week by fax form or voice mail. A seasonal baseline is calculated, and if the proportion of pneumonia and influenza (P&I) deaths for a given week exceeds the baseline value for that week by a statistically significant amount, then influenza-related deaths are said to be above the epidemic threshold.

State and territorial epidemiologists reports

Each week from October through May, epidemiologists from each state and territory report the estimated level of influenza activity in their area as *no activity*, *sporadic*, *regional*, or *widespread*. *Sporadic activity* is defined as sporadically occurring cases of influenza-like illness or culture-confirmed influenza with no outbreaks detected. *Regional activity* is outbreaks of influenza-like illness or culture-confirmed influenza occurring in counties in which the combined population is < 50% of the total state population. *Widespread activity* is outbreaks of influenza-like illness or culture-confirmed influenza in counties with a combined population of $\geq 50\%$ of the total state population. These reports come to EPO, CDC, via the National Electronic Telecommunications System for Surveillance (NETSS).

The information sources used to make this determination vary from state to state and may include sentinel physician networks, reports of increased visits for respiratory illness to hospital emergency rooms or outpatient clinics, school or worksite absenteeism reporting, nursing home surveillance, and reports of laboratory-diagnosed influenza. Local health departments should contact their state health department for state surveillance and reporting procedures.

XII. Enhancing surveillance

A number of activities can improve the detection and reporting of influenza infections as well as the comprehensiveness, timeliness, and quality of reporting.

Expanding reporting period. Health-care providers should be made aware that influenza cases can occur during any month of the year and that collecting and testing respiratory specimens during the summer months may provide valuable information about viruses likely to circulate during the upcoming influenza season.

Promoting awareness. Health-care providers should also be aware of the ease with which influenza infection can be confirmed by laboratory tests and of the importance of reporting influenza surveillance information at the local, state, and national levels.

Influenza surveillance information is available through the CDC Voice Information System by telephone at 1-888-232-3228, by fax (document number 361100) at 1-888-232-3299, or through the Internet.

Expanding sources of surveillance. Efforts should be made by state health departments to increase the number of sentinel physicians reporting influenza-like illness data each week to one participating physician per 250,000 population. Efforts should also be made to ensure that surveillance sites are geographically representative and cover all age groups.

Increasing awareness of local surveillance practices. State health departments should invite local health departments and health-care providers to participate in existing surveillance systems. In addition, health-care providers and surveillance personnel may be reminded of the importance of prompt reporting and reserving aliquots of clinical specimens used for rapid influenza antigen testing for possible virus isolation.

Sources of surveillance information. Health-care providers should be made aware that influenza surveillance information for the United States is updated weekly from October through May and is available through the CDC Voice Information System (influenza update) by telephone at 1-888-CDC-FACT (1-888-232-3228), or by fax (document number 361100) at 1-888-CDC-FAXX (1-888-232-3299). Influenza surveillance information is also available through the Internet at (<http://www.cdc.gov/ncidod/diseases/flu/weekly.htm>). Influenza activity updates are also published periodically in the *Morbidity and Mortality Weekly Report (MMWR)*.

XIII. Case investigation

Individual cases of influenza typically are not investigated. Exceptions to this are severe or fatal illnesses from unusual complications of influenza infection (e.g., encephalitis, myocarditis, rhabdomyolysis). Individual cases should also be investigated when the infecting virus is suspected or confirmed to be of swine or avian origin. In such a case, investigators should attempt to identify exposure to swine or birds and determine if the virus has been transmitted from human to human. Generally, avian and swine influenza viruses are identified as influenza A viruses that cannot be subtyped by hemagglutination inhibition testing using the standard H3N2 and H1N1 antisera included in the influenza reagent kit distributed by CDC. *Any influenza A virus that cannot be subtyped should be sent through the state health department to the CDC Influenza Branch immediately.* At the direction of the state health department, the Influenza Branch, CDC, may be contacted at 404-639-3591.

Any influenza A virus that cannot be subtyped should be sent by the state health department to the CDC Influenza Branch immediately.

References

1. Simonsen L, Clarke MJ, Williamson GD, et al. The impact of influenza epidemics on mortality: introducing a severity index. *Am J Public Health.* 1997;87:1944-1950.
2. Bridges CB, Fukuda K, Uyeki TM, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep.* 2002;51:1-31.
3. Simonsen L, Clarke MJ, Schonberger LB, et al. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. *J Infect Dis.* 1998;178:53-60.
4. Noble GR. Epidemiological and clinical aspects of influenza. In: Beare AS, ed. *Basic and applied influenza research.* 1982; Boca Raton: CRC Press.
5. Neuzil KM, Wright PF, Mitchel EF, Jr., et al. The burden of influenza illness in children with asthma and other chronic medical conditions. *J Pediatr.* 2000;137:856-864.
6. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. *N Engl J Med.* 2000;342:232-239.
7. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. *N Engl J Med.* 2000;342:225-231.
8. Palache AM. Influenza vaccines. A reappraisal of their use. *Drugs.* 1997;54:841-856.
9. Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. *Ann Intern Med.* 1994;121:947-952.
10. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. *N Engl J Med.* 1994;331:778-784.
11. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic. *JAMA.* 1985;253:1136-1139.
12. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA, eds. *Options for the control of influenza.* 1986; New York: Alan R. Liss, Inc.

13. Patriarca PA, Weber JA, Parker RA, et al. Risk factors for outbreaks of influenza in nursing homes. A case-control study. *Am J Epidemiol*. 1986;124:114-119.
14. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. *Lancet*. 2000;355:93-97.
15. Demicheli V, Jefferson T, Rivetti D, et al. Prevention and early treatment of influenza in healthy adults. *Vaccine*. 2000;18:957-1030.
16. Tominack RL, Hayden FG. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. *Infect Dis Clin North Am*. 1987;1:459-478.
17. Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. *Ann Pharmacother*. 1995;29:299-310.
18. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. *JAMA*. 2001;285:748-754.
19. Peters PH, Jr., Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. *J Am Geriatr Soc*. 2001;49:1025-1031.
20. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. *N Engl J Med*. 1999;341:1336-1343.
21. United States Department of Health and Human Services. *Healthy People 2010: With understanding and improving health and objectives for improving health*. 2000; Washington, D.C.: U.S. Government Printing Office.
22. Bellini WJ, Cox NJ. *Laboratory diagnosis of measles, influenza and other respiratory virus infections. Course manual*. 1995; Washington, D.C.: U.S. Department of Health and Human Services, Public Health Services.
23. Ziegler T, Cox NJ. Influenza viruses. In: Murray PR, Barron EJ, et al, eds. *Manual of clinical microbiology*. 1999; Washington, D.C.: ASM Press.